JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Overview Fund Activity
Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

84 hedge funds and large institutions have $81.8M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 16 closing their positions.

Holders
84
Holders Change
-1
Holders Change %
-1.18%
% of All Funds
1.87%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
16
Increased
31
Reduced
21
Closed
16
Calls
$18K
Puts
–
Net Calls
+$18K
Net Calls Change
-$3.38M

Top Buyers

1
JPMorgan Chase & Co
1
JPMorgan Chase & Co
New York
$2.09M
2
AQR Capital Management
2
AQR Capital Management
Connecticut
$443K
3
BCM
3
Bridgeway Capital Management
Texas
$1.01M
4
Two Sigma Investments
4
Two Sigma Investments
New York
$1.36M
5
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$471K

Top Sellers

1
Fidelity Investments
1
Fidelity Investments
Massachusetts
$3.39M
2
CC
2
Casdin Capital
New York
$0
3
Millennium Management
3
Millennium Management
New York
$735K
4
Man Group
4
Man Group
United Kingdom
$0
5
BlackRock
5
BlackRock
New York
$3.59M
Name Market Value Shares Shares
Change 		Shares
Change %
EC
101
EcoR1 Capital
California
– – – –
CFGS
102
Concourse Financial Group Securities
Alabama
– – – –
1 2 3 4
5